Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Jun 28, 2024

BT-549

RRID:CVCL_1092
Type: Cell Line

Proper Citation

(RRID:CVCL_1092)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1092

Proper Citation: (RRID:CVCL_1092)

Description: Cell line BT-549 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Defining Citation: PMID:1961733, PMID:6500159, PMID:7902062, PMID:9561029, PMID:9671407, PMID:10700174, PMID:10862037, PMID:10969801, PMID:11343771, PMID:15153330, PMID:15677628, PMID:15748285, PMID:16397213, PMID:16541312, PMID:17088437, PMID:17157791, PMID:18277095, PMID:18516279, PMID:19372543, PMID:19582160, PMID:19593635, PMID:19727395, PMID:20164919, PMID:20215515, PMID:20679594, PMID:21552935, PMID:21778573, PMID:22068913, PMID:22347499, PMID:22384151, PMID:22460905, PMID:22585861, PMID:22628656, PMID:23151021, PMID:23601657, PMID:23637631, PMID:23856246, PMID:23933261, PMID:24094812, PMID:24162158, PMID:24176112, PMID:24279929, PMID:24670534, PMID:25485619, PMID:25877200, PMID:25892236, PMID:25960936, PMID:25984343, PMID:26589293, PMID:27377824, PMID:27397505, PMID:27807467, PMID:28196595, PMID:28287265, PMID:28889351, PMID:30613774, PMID:30894373, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: Metabolome analysis., Omics: miRNA expression profiling., Omics: lncRNA expression profiling., Omics: Glycoproteome analysis by proteomics., Omics: Fluorescence phenotype profiling., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: CNV analysis., Omics: Array-based CGH., Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95

cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: JWGray breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Name: BT-549

Synonyms: BT 549, BT.549, BT549

Cross References: BTO:BTO:0002548, CLO:CLO_0002044, EFO:EFO_0001096, CLDB:cl7128, AddexBio:C0006017/4962, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-6647, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:HTB-122, BioGRID_ORCS_Cell_line:510, BioSample:SAMN03471380, BioSample:SAMN10988343, cancercelllines:CVCL_1092, CCRID:1101HUM-PUMC000336, CCRID:3101HUMTCHu93, Cell_Model_Passport:SIDM00122, ChEMBL-Cells:CHEMBL3308490, ChEMBL-Targets:CHEMBL614072, CLS:300132, Cosmic:687466, Cosmic:850826, Cosmic:871140, Cosmic:875881, Cosmic:877446, Cosmic:897414, Cosmic:904353, Cosmic:934522, Cosmic:949188, Cosmic:974237, Cosmic:1010925, Cosmic:1018476, Cosmic:1044204, Cosmic:1044234, Cosmic:1046924, Cosmic:1047700, Cosmic:1092593, Cosmic:1136371, Cosmic:1152525, Cosmic:1175830, Cosmic:1176638, Cosmic:1287920, Cosmic:1289385, Cosmic:1305386, Cosmic:1308998, Cosmic:1312372, Cosmic:1434948, Cosmic:1603193, Cosmic:1609466, Cosmic:1995350, Cosmic:1998435, Cosmic:2036671, Cosmic:2164983, Cosmic:2301524, Cosmic:2318374, Cosmic:2361359, Cosmic-CLP:905951, DepMap:ACH-000288, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905951, GEO:GSM2121, GEO:GSM50181, GEO:GSM50245, GEO:GSM217614, GEO:GSM274638, GEO:GSM274662, GEO:GSM320176, GEO:GSM344343, GEO:GSM344393, GEO:GSM350517, GEO:GSM378149, GEO:GSM421863, GEO:GSM750775, GEO:GSM783947, GEO:GSM799318, GEO:GSM799381, GEO:GSM827358, GEO:GSM839031, GEO:GSM847199, GEO:GSM847454, GEO:GSM846287, GEO:GSM843479, GEO:GSM843480, GEO:GSM843477, GEO:GSM843478, GEO:GSM886894, GEO:GSM887959, GEO:GSM1008893, GEO:GSM1053686, GEO:GSM1153387, GEO:GSM1172943, GEO:GSM1172855, GEO:GSM1181340, GEO:GSM1181341, GEO:GSM1214578, GEO:GSM1238130, GEO:GSM1374412, GEO:GSM1374413, GEO:GSM1401657, GEO:GSM1669632, GEO:GSM2124662, IARC_TP53:5, IARC_TP53:28243, IBRC:C10151, ICLC:HTL02006, KCB:KCB 2011118YJ, LiGeA:CCLE_360, LINCS_HMS:50108, LINCS_LDP:LCL-1310, Lonza:116, NCI-DTP:BT-549, PharmacoDB:BT549_111_2019, PRIDE:PXD005292, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_1092, PubChem_Cell_line:CVCL_1092, SKY/M-FISH/CGH:1458, SLKBase:3393, TOKU-E:696, Wikidata:Q54798471

ID: CVCL_1092

Record Creation Time: 20220427T215414+0000

Record Last Update: 20240503T071624+0000

Ratings and Alerts

No rating or validation information has been found for BT-549.

No alerts have been found for BT-549.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 2356 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Gali A, et al. (2024) Protein kinase D drives the secretion of invasion mediators in triple-negative breast cancer cell lines. iScience, 27(2), 108958.

Liu X, et al. (2024) USP7 reduces the level of nuclear DICER, impairing DNA damage response and promoting cancer progression. Molecular oncology, 18(1), 170.

Rybinska I, et al. (2024) SAA1-dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness. International journal of cancer.

Yang Q, et al. (2024) Reduced representative methylome profiling of cell-free DNA for breast cancer detection. Clinical epigenetics, 16(1), 33.

Liu S, et al. (2024) TNFRSF19 promotes endoplasmic reticulum stress-induced paraptosis via the activation of the MAPK pathway in triple-negative breast cancer cells. Cancer gene therapy, 31(2), 217.

Chou WC, et al. (2024) Genetic insights into carbohydrate sulfotransferase 8 and its impact on the immunotherapy efficacy of cancer. Cell reports, 43(1), 113641.

Zhang Y, et al. (2024) Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer. Cell metabolism, 36(1), 193.

Liu CC, et al. (2024) Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer. Cell reports. Medicine, 5(2), 101396.

Cottrell KA, et al. (2023) Induction of viral mimicry upon loss of DHX9 and ADAR1 in breast cancer cells. bioRxiv : the preprint server for biology.

Lin CH, et al. (2023) Carboxyl-terminal modulator protein facilitates tumor metastasis in triple-negative breast cancer. Cancer gene therapy, 30(3), 404.

He XY, et al. (2023) LncRNA modulates Hippo-YAP signaling to reprogram iron metabolism. Nature communications, 14(1), 2253.

Vidal-Cruchez O, et al. (2023) KRAS and NRAS Translation Is Increased upon MEK Inhibitors-Induced Processing Bodies Dissolution. Cancers, 15(12).

Liu Y, et al. (2023) Cadherin-11 increases tumor cell proliferation and metastatic potential via Wnt pathway activation. Molecular oncology, 17(10), 2056.

Zheng Y, et al. (2023) Silencing TRAIP suppresses cell proliferation and migration/invasion of triple negative breast cancer via RB-E2F signaling and EMT. Cancer gene therapy, 30(1), 74.

Dong LF, et al. (2023) circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape. Journal for immunotherapy of cancer, 11(6).

Li J, et al. (2023) Integrating machine learning algorithms to systematically assess reactive oxygen species levels to aid prognosis and novel treatments for triple -negative breast cancer patients. Frontiers in immunology, 14, 1196054.

Shrestha M, et al. (2023) CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer. Oncogenesis, 12(1), 29.

Gallego-Paez LM, et al. (2023) TLN1 contains a cancer-associated cassette exon that alters talin-1 mechanosensitivity. The Journal of cell biology, 222(5).

Lin Q, et al. (2023) Long noncoding RNA HITT coordinates with RGS2 to inhibit PD-L1 translation in T cell immunity. The Journal of clinical investigation, 133(11).

Zhang Y, et al. (2023) Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer. Breast cancer research : BCR, 25(1), 75.